Cost-effectiveness of lung cancer screening in Canada

JAMA Oncology

Volumn 1, Issue 6, 2015, Pages 807-813

  Goffin, John R ^a   Flanagan, William M ^b   Miller, Anthony B ^c   Fitzgerald, Natalie R ^d   Memon, Saima ^d   Wolfson, Michael C ^e   Evans, William K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b STATISTICS CANADA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Canadian Partnership Against Cancer   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; AGE; AGED; CANADA; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE; PREVENTION AND CONTROL; PROCEDURES; PROTECTION; QUALITY ADJUSTED LIFE YEAR; RADIATION DOSE; RADIOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TIME;

AGE FACTORS; AGED; CANADA; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTECTIVE FACTORS; QUALITY-ADJUSTED LIFE YEARS; RADIATION DOSAGE; RISK ASSESSMENT; RISK FACTORS; SMOKING; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84965092975     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.2472     Document Type: Article

References (51)

1. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto: Canadian Cancer Society; 2013.
2. Canadian Partnership Against Canada. Lung cancer in Canada: a supplemental system performance report. May 2011.http://www.cancerview.ca/idc/groups/public/documents/webcontent/cpac015706.pdf. Accessed June 15, 2015.
3. Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.
4. Laroche C, Wells F, Coulden R, et al. Improving surgical resection rate in lung cancer. Thorax. 1998; 53(6):445-449.
5. Oken MM, Hocking WG, Kvale PA, et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865-1873.
6. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS; International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763-1771.
7. Infante M, Cavuto S, Lutman FR, et al; DANTE Study Group. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180(5): 445-453.
8. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology. 2005;235(1):259-265.
9. Veronesi G, Bellomi M, Scanagatta P, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. J Thorac Cardiovasc Surg. 2008;136(3):611-617.
10. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med. 2008; 178(9):956-961.
11. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5): 395-409.
12. Evans WK, Wolfson M, Flanagan WM, et al. The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model. Lung Cancer Manag. 2012;1(1): 25-33.
13. Evans WK, Wolfson MC, Flanagan WM, et al. Canadian Cancer Risk Management Model: evaluation of cancer control. Int J Technol Assess Health Care. 2013;29(2):131-139.
14. Flanagan WM, Evans WK, Fitzgerald NR, Goffin JR, Miller AB, Wolfson MC. Performance of the cancer risk management model lung cancer screening module. Health Rep. 2015;26(5):11-18.
15. The Canadian Partnership Against Cancer. Cancer Risk Management Model: an evidence-based tool to inform cancer control decision-making. 2011. http://cancerview.ca/cancerriskmanagement Accessed June 18, 2015.
16. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29-34.
17. Douillard JY, Tribodet H, Aubert D, et al; LACE Collaborative Group. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol. 2010; 5(2):220-228.
18. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and Harms of Computed Tomography Lung Cancer Screening Programs for High-Risk Populations. AHRQ Publication No. 13-05196-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
19. Patz EF Jr, Pinsky P, Gatsonis C, et al; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174(2):269-274.
20. Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol. 2007; 25(2):196-202.
21. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841-1848.
22. Tran K, Asakawa K, Cimon K, et al. Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.
23. World Health Organization. Cost-effectiveness thresholds; Cost effectiveness and strategic planning (WHO-CHOICE). 2015. http://www.who.int/choice/costs/CER-thresholds/en/. Accessed May 14, 2014.
24. Statistics Canada. Gross domestic product per capita, Canada, provinces and territories, 2005/2006 to 2009/2010 (in current dollars). 2013; http://www.statcan.gc.ca/pub/81-595-m/2011095/tbl/tbla.34-eng.htm. Accessed May 21, 2015.
25. Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PLoS One. 2013;8(8):e71379.
26. Black WC, Gareen IF, Soneji SS, et al; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014;371(19): 1793-1802.
27. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013; 369(3):245-254.
28. Maisonneuve P, Bagnardi V, Bellomi M, et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev Res (Phila). 2011;4(11): 1778-1789.
29. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728-736.
30. Lopes Pegna A, Picozzi G, Falaschi F, et al; ITALUNG Study Research Group. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol. 2013;8(7): 866-875.
31. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308-315.
32. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease: the randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4): 296-301.
33. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003;289(3):313-322.
34. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-2429.
35. Tammemägi MC, Berg CD, Riley TL, Cunningham CR, Taylor KL. Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst. 2014;106(6):dju084.
36. Canadian Partnership Against Cancer. Breast cancer control in Canada: a system performance special focus report. Toronto; 2012. http://www.cancerview.ca/idc/groups/public/documents/webcontent/breast-cancer-control-rep.pdf. Accessed June 15, 2015.
37. Public Health Agency of Canada. Organized breast cancer screening programs in Canada: report on program performance in 2003 and 2004. Ottawa. 2008. http://www.phac-aspc.gc.ca/publicat/2008/obcsp-podcs-03-04/index-eng.php. Accessed June 15, 2015.
38. Tatla RK, Paszat LF, Bondy SJ, Chen Z, Chiarelli AM, Mai V. Socioeconomic status & returning for a second screen in the Ontario breast screening program. Breast. 2003;12(4):237-246.
39. Cancer Care Ontario. ColonCancerCheck 2010 program report. Toronto, Canada. 2012. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=156747. Accessed June 22, 2015.
40. Reid JL, Hammond D, Driezen P. Socio-economic status and smoking in Canada, 1999-2006: has there been any progress on disparities in tobacco use? Can J Public Health. 2010;101(1):73-78.
41. Veronesi G, Maisonneuve P, Rampinelli C, et al. Computed tomography screening for lung cancer: results of ten years of annual screening and validation of cosmos prediction model. Lung Cancer. 2013;82(3):426-430.
42. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449-2460.
43. Knudsen AB, McMahon PM, Gazelle GS. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol. 2007;25 (2):203-208.
44. Cressman S, Lam S, Tammemagi MC, et al; Pan-Canadian Early Detection of Lung Cancer Study Team. Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada. J Thorac Oncol. 2014;9(10): 1449-1458.
45. Goffin JR, Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013;35(9):1282-1303.
46. Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-2177.
47. Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2014;6(1):4-15.
48. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33-38.
49. Roberts H, Walker-Dilks C, Sivjee K, et al. Screening high-risk populations for lung cancer. Toronto: Cancer Care Ontario; 2013.
50. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy. 2006;11(1):46-51.
51. Canadian Institute for Health Information. National Health Expenditure Trends. 2014. http://apps.cihi.ca/mstrapp/asp/Main.aspx?Server =apmstrextprd-i&project=Quick+Stats&uid =pce-pub-en&pwd=&evt=2048001 &visualizationMode=0&documentID =9D0E83BC4BACDADE9D4938B338C6B6D5. Accessed April 4, 2015.